As the popularity of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide and tirzepatide—skyrockets, a new clinical challenge has emerged for plastic surgeons. These medications, which have revolutionized the treatment of type 2 diabetes and obesity, are increasingly being used by patients preparing for or recovering from body contouring procedures. A groundbreaking study published in the April issue of Plastic and Reconstructive Surgery®, the official journal of the American Society of Plastic Surgeons (ASPS), now sheds light on how these drugs influence surgical outcomes, revealing a complex, nuanced reality for patients and their surgeons.
Main Facts: A Shift in the Surgical Landscape
The study, led by Dr. Zachary Andrew Koenig of the West Virginia University School of Medicine, examines the intersection of pharmacological weight loss and surgical intervention. Specifically, the research focuses on patients undergoing abdominal panniculectomy—a procedure designed to remove the "pannus," or the hanging apron of excess skin and fat that often remains after significant weight loss.
The core takeaway from the analysis is that while GLP-1 receptor agonists (GLP1ra) do not appear to increase the risk of catastrophic surgical complications, they do create "subtle" yet significant shifts in how a patient heals. The findings suggest that clinicians must move away from a "one-size-fits-all" approach to preoperative care, particularly as the prevalence of these medications continues to climb in patient populations.
Chronology: A Decade of Data in West Virginia
To understand the long-term impact of these medications, Dr. Koenig and his team conducted a rigorous 10-year retrospective analysis, spanning from 2013 to 2023. This decade-long window allowed researchers to capture the meteoric rise of GLP-1 usage, which has mirrored national trends. West Virginia, which boasts some of the highest prescription rates for these drugs in the United States, provided a unique and robust laboratory for this study.
The Timeline of Clinical Integration:
- 2013–2018: GLP-1 usage among surgical candidates was relatively low, primarily reserved for patients with established type 2 diabetes.
- 2019–2021: The approval and marketing of newer, more potent GLP-1 medications led to a sharp, visible increase in their use among individuals preparing for elective aesthetic and reconstructive procedures.
- 2022–2023: Researchers observed a significant portion of their patient cohort (21.7%) entering the operating room with these medications in their system, prompting the formal study to evaluate safety profiles.
By isolating a cohort of 373 patients and excluding those who had undergone concurrent bariatric or hernia surgeries, the researchers were able to create a "clean" data set that specifically highlights the effects of GLP-1s on isolated panniculectomy outcomes.
Supporting Data: The Paradox of Healing
The data presented by the West Virginia University team highlights a fascinating physiological paradox. When comparing patients on GLP-1 therapy to those who were not, the outcomes were not universally positive or negative; rather, they were mixed.
Comparative Complication Rates:
- Delayed Wound Healing: Patients on GLP-1 medications faced an 18.5% rate of delayed wound healing, compared to just 7.5% in the control group. This represents a statistically significant increase that warrants clinical attention.
- Seroma Formation: Conversely, GLP-1 users experienced a significantly lower rate of seroma (fluid accumulation under the skin)—4.9% compared to 14.0% in non-users.
- Equivalent Risks: Rates of more severe complications, such as surgical site infection, wound dehiscence (reopening of the incision), and the need for hospital readmission, remained comparable between the two groups.
The researchers noted that the GLP-1 group was, on average, dealing with more chronic health challenges—such as hypertension, chronic obstructive pulmonary disease (COPD), and type 2 diabetes—than the control group. Despite these higher-risk baseline profiles, the body contouring procedures remained broadly safe. However, the higher incidence of delayed wound healing suggests that the drug may alter the body’s inflammatory or metabolic response to the trauma of surgery, even if it doesn’t cause systemic failure.
Official Responses: The Expert Perspective
Dr. Zachary Andrew Koenig, the lead author of the study, emphasizes that the medical community is still in the "learning phase" regarding these medications. "As GLP-1 receptor agonists become increasingly integrated into the care of patients undergoing body contouring, our findings suggest that these drugs may have subtle effects on wound healing, even if they don’t increase overall surgical risks," Dr. Koenig noted.
The American Society of Plastic Surgeons has long advocated for evidence-based practice, and this study serves as a critical bridge between modern endocrinology and surgical expertise. The researchers argue that the findings "reinforce that while GLP1ra appear broadly safe perioperatively, their impact on soft tissue healing… may involve unique mechanisms not yet fully understood."
Because the study specifically highlights a regional trend in West Virginia, experts suggest that national multicenter studies are the next logical step to validate these findings across more diverse demographic and geographic groups.
Implications: Changing the Preoperative Protocol
The implications of this study are profound for both the surgeon and the patient. As the landscape of weight management shifts, plastic surgeons are increasingly finding themselves as part of a patient’s multidisciplinary care team.
1. Proactive Management of Healing
Because of the increased risk of delayed wound healing, surgeons may need to adjust their postoperative care. This could include longer durations of wound dressing, more frequent follow-up visits, or the use of advanced topical healing agents to support tissue recovery in patients identified as GLP-1 users.
2. The Need for Formal Guidelines
Currently, there is no universal consensus on whether a patient should stop taking GLP-1 medications prior to surgery. While some surgeons advise a "washout" period, others worry about the potential for metabolic fluctuations. This study provides the data foundation necessary to begin drafting formal, specialty-wide guidelines.
3. Patient Education and Risk Assessment
Patients considering body contouring who are currently on weight loss medications should be informed of these specific risks. A transparent conversation regarding the potential for slower wound healing allows for better patient expectations and compliance with recovery instructions.
4. A New Era of Surgical Research
The study acknowledges that the "complex and nuanced interplay" between these drugs and surgical recovery is likely linked to the drugs’ systemic effects on digestion, inflammation, and metabolic homeostasis. Future research will likely focus on whether temporary cessation of these drugs prior to surgery could mitigate the risk of delayed healing while still allowing the patient to maintain the benefits of their weight loss journey.
Conclusion: A Nuanced Path Forward
The integration of GLP-1 medications into the daily lives of millions of people is one of the most significant medical developments of the 21st century. For the plastic surgery community, this represents an opportunity to improve patient outcomes by optimizing body weight and metabolic health prior to surgery.
However, as the study in Plastic and Reconstructive Surgery® demonstrates, this medical progress comes with its own set of requirements. Surgeons must remain vigilant, observant, and willing to evolve their techniques as the pharmacological profile of their patients changes. While the "overall surgical risk" has not been deemed excessive, the "subtle" impacts on wound healing serve as a reminder that every medication carries a trade-off.
As the medical community continues to collect data, the path forward will involve a delicate balance of leveraging the weight-loss success provided by GLP-1s while carefully managing the specific recovery needs of the patients who use them. For now, the takeaway is clear: the surgical landscape is changing, and it requires a more personalized, data-driven approach to ensure that patients not only reach their aesthetic goals but do so with the highest standard of safety and healing.
For more information on the study, "Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis" (doi: 10.1097/PRS.0000000000012405), please visit the official website of Plastic and Reconstructive Surgery or the Wolters Kluwer medical portfolio.
About the Author
